Product Pipeline

OriCell Therapeutics focuses on the unmet clinical needs for the treatment of liver cancer, ovarian cancer, gastric cancer, cervical cancer, and non-small cell lung cancer. It has developed several dozen pipelines for independently innovative cell drugs and monospecific/bispecific antibodies targeting solid tumors. Among them, six immune cell therapy products for tumors have been approved by the ethical committee of the hospital and entered the stage of exploratory clinical development. The Investigational New Drug (IND) application for four products has been initiated. The application materials for the first product will be submitted in the first quarter of 2022. The IND application for the other 3 products is currently underway.

CAR-T
OriCell Therapeutics Proprietary Pipeline Development OriCell Therapeutics External Co-Development

Cell Therapy
Programs
Indication
POC
IND
Phase I
Phase II/III
IP
Ori®-C101
HCC
Global
Ori®C604
MM
Global
Ori®CAR-017
R/RMM
Global
Ori®C321
R/RMM
Global
Ori®C613
Solid Tumor
Global
Ori®C615
Solid Tumor
Global
Ori®C623
Solid Tumor
Global
Ori®C624
Solid Tumor
Global
Ori®C632
NSCLC
Global

Antibody

Antibody
candidate
Target
Indication
Discovery
Optimization
Preclinical
IND
Enabling
IND
Phase I
Phase II/III
IP
Ori®-Bs-001
PD-L1/4-1BB
Solid tumor
Candidate fully validated (Partnered to Antengene)
Global
Ori®A236
4-1BB
Solid tumor
Candidate fully validated
Global
Ori®A214
PD-L1
Solid tumor
Candidate fully validated
Global
Ori®A626
PVRIG
Solid Tumor
Candidate fully validated
China
Ori®A611
TIGIT
Solid tumor
Candidate fully validated
Global
Ori®A610
PD-L1/TIGIT
Solid tumor
Candidate fully validated
Global
Ori®A364
PD-L1/CLDN 18.2
Solid tumor
Candidate fully validated
Global
Ori®A362
4-1BB/CLDN 18.2
Solid tumor
Candidate fully validated
Global
Ori®A631
CD73/CD39
Solid Tumor
Candidate fully validated

CAR-T
OriCell Therapeutics Proprietary Pipeline Development OriCell Therapeutics External Co-Development

Ori®-C101

Indication: HCC

IP:Global

Ori®C604

Indication: MM

IP:Global

Ori®CAR-017

Indication: R/RMM

IP:Global

Ori®C321

Indication: R/RMM

IP:Global

Ori®C613

Indication: Solid Tumor

IP:Global

Ori®C615

Indication: Solid Tumor

IP:Global

Ori®C623

Indication: Solid Tumor

IP:Global

Ori®C624

Indication: Solid Tumor

IP:Global

Ori®C632

Indication: NSCLC

IP:Global

Antibody

Ori®-Bs-001

Target: PD-L1/4-1BB

Indication: Solid tumor

IP:Global

Ori®A236

Target: 4-1BB

Indication: Solid tumor

IP:Global

Ori®A214

Target: PD-L1

Indication: Solid tumor

IP:Global

Ori®A626

Target: PVRIG

Indication: Solid Tumor

IP:China

Ori®A611

Target: TIGIT

Indication: Solid tumor

IP:Global

Ori®A610

Target: PD-L1/TIGIT

Indication: Solid tumor

IP:Global

Ori®A364

Target: PD-L1/CLDN 18.2

Indication: Solid tumor

IP:Global

Ori®A362

Target: 4-1BB/CLDN 18.2

Indication: Solid tumor

IP:Global

Ori®A631

Target: CD73/CD39

Indication: Solid Tumor

IP: